BridgeBio Oncology Therapeutics Inc.
NASDAQ:BBOTBiotechnology
Healthcare
$1.86 -0.39%
-$0.03 today
- Market cap
- $149.27M
- Beta
- 0.29
- P/E (TTM)
- -1.5
- EPS (TTM)
- -$4.95
52W Low $7.00High $14.87
Volume 0.37M
Average 0.37M
Cash Flow
Check whether earnings turn into cash.
Operating Cash Flow
-$113.89M
FY 2025 · Annual
Investing Cash Flow
$73.33M
FY 2025 · Annual
Financing Cash Flow
$383.40M
FY 2025 · Annual
+105.6% YoYCash Flow Statement
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (74) | (3.52K) | (41.69K) | 7.6M | (134.04M) |
| Depreciation & Amortization | 0 | 0 | 0 | 0 | 610K |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 0 | 0 | 0 | 271.57K | 5.87M |
| Change in Working Capital | 0 | 0 | 15K | (104.61K) | 6.43M |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 0 | 0 | 0 | 172.52K | (1.84M) |
| Other Working Capital | 0 | 0 | 15K | (277.13K) | 8.27M |
| Other Non-Cash Items | 74 | 3.52K | 26.69K | (8.53M) | 7.23M |
| Operating Cash Flow | 0 | 0 | (52.08M) | (763.82K) | (113.89M) |
| Capital Expenditures | 0 | 0 | 0 | 0 | (606K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | (184M) | (83.93M) |
| Sales of Investments | 0 | 0 | 0 | 0 | 157.86M |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | 0 | 0 | 0 | (184M) | 73.33M |
| Debt Repayment | 0 | 0 | 0 | (209.85K) | 0 |
| Common Stock Issued | 0 | 0 | 0 | 187.25M | 395.72M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 0 | 0 | 0 | (578.55K) | (12.32M) |
| Financing Cash Flow | 0 | 0 | 0 | 186.46M | 383.4M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 0 | 0 | 225K | 1.7M | 342.84M |
| Free Cash Flow | 0 | 0 | (52.49M) | (763.82K) | (114.5M) |
Free Cash Flow
Net Income to FCF bridge
FY2025
= Net Income-$134.0M
+ D&A$610.0K
+ Stock-Based Comp$5.9M
+ Deferred Tax$0
+ Working Capital$6.4M
+ Other Non-Cash$7.2M
= Operating Cash Flow-$113.9M
- Capex-$606.0K
= Free Cash Flow-$114.5M
Analysis
FY2025 free cash flow is -$114.5M. FCF conversion is 85.4% of net income. Operating cash flow was -$113.9M, with capex of -$606.0K. The largest bridge item is Other Non-Cash at $7.2M.
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| SC 13G/A | SC 13G/A filing | Nov 13, 2026 | |
| 10-Q | Quarterly report | Nov 10, 2026 | |
| 8-K | Current report | Nov 10, 2026 | |
| 8-K | Current report | Nov 5, 2026 | |
| 4 | Statement of changes in beneficial ownership | Oct 23, 2026 |
Does BBOT generate free cash flow?
BridgeBio Oncology Therapeutics Inc. (BBOT) generated -$114.50M of free cash flow in fiscal 2025.
How much operating cash flow does BBOT produce?
Operating cash flow was -$113.89M, before capital expenditures of $606,000.00.
Continue the stock analysis
Jump to another research area for this company.